ATE428731T1 - Therapeutische antiköper mit reduzierten nebenwirkungen - Google Patents

Therapeutische antiköper mit reduzierten nebenwirkungen

Info

Publication number
ATE428731T1
ATE428731T1 AT03765177T AT03765177T ATE428731T1 AT E428731 T1 ATE428731 T1 AT E428731T1 AT 03765177 T AT03765177 T AT 03765177T AT 03765177 T AT03765177 T AT 03765177T AT E428731 T1 ATE428731 T1 AT E428731T1
Authority
AT
Austria
Prior art keywords
side effects
therapeutic antibodies
reduced side
therapeutic
protein
Prior art date
Application number
AT03765177T
Other languages
English (en)
Inventor
Herman Waldmann
Mark Frewin
Lisa Gilliland
Silva Graca Luis Da
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation filed Critical Isis Innovation
Application granted granted Critical
Publication of ATE428731T1 publication Critical patent/ATE428731T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
AT03765177T 2002-07-23 2003-07-23 Therapeutische antiköper mit reduzierten nebenwirkungen ATE428731T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39793402P 2002-07-23 2002-07-23
PCT/GB2003/003156 WO2004009638A1 (en) 2002-07-23 2003-07-23 Therapeutic antibodies with reduced side effects

Publications (1)

Publication Number Publication Date
ATE428731T1 true ATE428731T1 (de) 2009-05-15

Family

ID=30771146

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03765177T ATE428731T1 (de) 2002-07-23 2003-07-23 Therapeutische antiköper mit reduzierten nebenwirkungen

Country Status (8)

Country Link
US (2) US20040109855A1 (de)
EP (1) EP1523503B1 (de)
JP (1) JP4583170B2 (de)
AT (1) ATE428731T1 (de)
AU (1) AU2003260686B2 (de)
DE (1) DE60327205D1 (de)
ES (1) ES2323457T3 (de)
WO (1) WO2004009638A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4334866B2 (ja) 2000-10-09 2009-09-30 アイシス イノヴェイション リミテッド 治療用抗体
EP2178914A2 (de) 2007-08-15 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Monospezifische und multispezifische antikörper und anwendungsverfahren
CA2697032C (en) * 2007-08-22 2021-09-14 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
AU2013202755B2 (en) * 2007-08-22 2016-05-12 Cytomx Therapeutics, Inc. Activatable binding polypeptides and methods of identification and use thereof
AU2016213702C1 (en) * 2007-08-22 2018-11-29 Cytomx Therapeutics, Inc. Activatable binding polypeptides and methods of identification and use thereof
CA2749339A1 (en) 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
RU2011138951A (ru) 2009-02-23 2013-03-27 Сайтомкс Терапьютикс, Инк. Пропротеины и способы их применения
RU2713121C2 (ru) 2012-04-27 2020-02-03 Сайтомкс Терапьютикс, Инк. Активируемые антитела, которые связываются с рецептором эпидермального фактора роста, и способы их применения
AU2013266069B2 (en) * 2012-05-25 2018-03-15 Sloan Kettering Institute For Cancer Research Methods for treating GI syndrome and graft versus host disease
WO2013192546A1 (en) 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and mehtods of using the same
US9127053B2 (en) 2012-06-22 2015-09-08 Cytomx Therapeutics, Inc. Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
WO2014052462A2 (en) 2012-09-25 2014-04-03 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
AU2014204015A1 (en) 2013-01-04 2015-07-09 Cytomx Therapeutics, Inc. Compositions and methods for detecting protease activity in biological systems
EP3003370B1 (de) 2013-05-28 2020-01-22 Dcb-Usa Llc Antikörpersperrer zur inaktivierung von proteinarzneimittel
CA2913732A1 (en) 2013-06-04 2014-12-11 Cytomx Therapeutics, Inc. Compositions and methods for conjugating activatable antibodies
AU2014292924B2 (en) 2013-07-25 2019-11-21 Cytomx Therapeutics, Inc Multispecific antibodies, multispecific activatable antibodies and methods of using the same
US20150087810A1 (en) 2013-09-25 2015-03-26 Cytomx Therapeutics, Inc. Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use Thereof
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2015089283A1 (en) 2013-12-11 2015-06-18 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
DK3628328T3 (da) 2014-01-31 2022-12-05 Cytomx Therapeutics Inc Matriptase- og u-plasminogen-aktivatorsubstrater og andre spaltelige dele og fremgangsmåder til anvendelse deraf
JP7020909B2 (ja) 2014-07-25 2022-02-16 シトムクス セラピューティクス，インコーポレイティド 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
EP3268392A2 (de) 2015-03-13 2018-01-17 CytomX Therapeutics, Inc. Anti-pdl1-antikörper, aktivierbare anti-pdl1-antikörper und verfahren zur verwendung davon
JP7028648B2 (ja) 2015-05-04 2022-03-02 サイトメックス セラピューティクス インコーポレイテッド 抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法
JP2018520092A (ja) 2015-05-04 2018-07-26 サイトメックス セラピューティクス インコーポレイテッド 抗ＩＴＧａ３抗体、活性化可能抗ＩＴＧａ３抗体、およびその使用方法
PL3292149T3 (pl) 2015-05-04 2022-03-21 Cytomx Therapeutics, Inc. Aktywowalne przeciwciała anty-cd71 i sposoby ich stosowania
SG10201913303XA (en) 2015-07-13 2020-03-30 Cytomx Therapeutics Inc Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
JP7039582B2 (ja) 2016-11-03 2022-03-22 ブリストル－マイヤーズ スクイブ カンパニー 活性化可能な抗ｃｔｌａ－４抗体およびその使用
WO2018107125A1 (en) 2016-12-09 2018-06-14 Seattle Genetics, Inc. Bivalent antibodies masked by coiled coils
AU2018278327B2 (en) 2017-06-01 2023-03-16 Cytomx Therapeutics, Inc. Activatable anti-pdl1 antibodies and methods of use thereof
EA202090247A1 (ru) 2017-07-14 2020-05-12 Цитомкс Терапьютикс, Инк. Антитела против cd166 и их применения
EP3668545A2 (de) 2017-08-16 2020-06-24 Bristol-Myers Squibb Company Prodrug-bindungsfähige antikörper, prodrugs davon und verfahren zur verwendung und herstellung
US11472889B2 (en) 2017-10-14 2022-10-18 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
JP2022512124A (ja) 2018-12-06 2022-02-02 シートムエックス セラピューティクス，インコーポレイテッド マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法
WO2020247574A1 (en) 2019-06-05 2020-12-10 Seattle Genetics, Inc. Methods of purifying masked antibodies
WO2020247572A1 (en) 2019-06-05 2020-12-10 Seattle Genetics, Inc. Masked antibody formulations
US20220251206A1 (en) 2019-06-11 2022-08-11 Bristol-Myers Squibb Company Anti-ctla4 antibody prodruggable (probody) at a cdr position
KR20220167295A (ko) 2020-04-10 2022-12-20 싸이톰스 테라퓨틱스, 인크. 활성화가능한 사이토카인 작제물과 관련된 조성물 및 방법
KR20230157448A (ko) 2021-03-16 2023-11-16 싸이톰스 테라퓨틱스, 인크. 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법
EP4370211A1 (de) 2021-07-14 2024-05-22 Seagen Inc. Antikörpermaskierende domänen
WO2023049825A1 (en) 2021-09-24 2023-03-30 Seagen Inc. Improved antibody masking domains
WO2023222580A1 (en) 2022-05-16 2023-11-23 Byondis B.V. Novel masked antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9603507D0 (en) * 1996-02-20 1996-04-17 Isis Innovation Antibody variants
US5990286A (en) * 1996-12-18 1999-11-23 Techniclone, Inc. Antibodies with reduced net positive charge
JP4334866B2 (ja) * 2000-10-09 2009-09-30 アイシス イノヴェイション リミテッド 治療用抗体
CA2438513C (en) * 2001-02-19 2013-08-13 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified anti-egfr antibodies with reduced immunogenicity

Also Published As

Publication number Publication date
AU2003260686A1 (en) 2004-02-09
JP4583170B2 (ja) 2010-11-17
ES2323457T3 (es) 2009-07-16
WO2004009638A1 (en) 2004-01-29
EP1523503A1 (de) 2005-04-20
AU2003260686B2 (en) 2009-11-26
JP2006506333A (ja) 2006-02-23
DE60327205D1 (de) 2009-05-28
US20130028893A1 (en) 2013-01-31
US20040109855A1 (en) 2004-06-10
EP1523503B1 (de) 2009-04-15

Similar Documents

Publication Publication Date Title
DE60327205D1 (de) Therapeutische antiköper mit reduzierten nebenwirkungen
ATE513563T1 (de) Therapeutische und toleranz-induzierende antikörper
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
RS52775B (en) CD19 OPTIMIZED ANTIBODY
ATE441418T1 (de) Verwendung von treprostinil zur verbesserung der nierenfunktion
EA200702402A1 (ru) Агенты, связывающие склеростин
EA200601603A1 (ru) Миметические антитела glp-1 человека, композиции, способы и применения
MX2010005966A (es) Conjugados de anticuerpo monoclonal-molecula asociada dirigidos a la proteina tirosina-cinasa 7 (ptk7).
EA200700108A1 (ru) Новое применение пептидных соединений для лечения идиопатического тремора и других синдромов, ассоциированных с тремором
EA200401398A1 (ru) Замещённые фенилацетамиды и их применение в качестве активаторов глюкокиназы
ATE476992T1 (de) Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper
EA200800812A1 (ru) Композиции антитела против cd3
BR122018016045B8 (pt) proteína variante otimizada
RS52780B (en) MEANS OF PREVENTION AND TREATMENT OF DISORDERS CONCERNING MODULATION OF RYR RECEPTORS
AR075790A2 (es) Anticuerpos anti -ngf humanos neutralizantes como inhibidores selectivos de la via de ngf (factor de crecimiento neural)
RS54468B1 (en) MONOCLONAL ANTIBODIES AGAINST CLAUDINE-18 FOR THE CANCER TREATMENT
BRPI0314814B8 (pt) anticorpo compreendendo uma variante de fc
BR0214621A (pt) Moléculas de automontagem
RS53685B1 (en) HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, METHODS AND APPLICATIONS
EA200901500A1 (ru) Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека
PE20120340A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
EA200601670A1 (ru) Конъюгаты гидроксиалкилкрахмала и белка
NO20091064L (no) Antistoffer mot IL-17A
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
EA200700702A1 (ru) Аналоги локсапина и способы их применения

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties